{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T07:58:19Z","timestamp":1785225499561,"version":"3.55.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017501","name":"Science-Health Joint Medical Scientific Research Project of Chongqing","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Dilated cardiomyopathy (DCM) has brought great damage to the patients' health and social economy. The number of patients with recovered dilated cardiomyopathy (recDCM) has increased over the years as treatment progresses. However, there is a lack of relevant evidence to support the clinical management of patients with recDCM, thereby, the recommendations in guidelines remains sparse. Accordingly, the exploration of recDCM is important to improve patient prognosis and reduce societal burden. This is an open-label, randomized controlled, prospective study that will compare the safety and efficacy of original dose and halved dose of neurohumoral blockades for patients with recDCM.<\/jats:p><jats:sec><jats:title>Methods<\/jats:title><jats:p>An open-label, randomized controlled, prospective study will be conducted among eligible patients with recDCM. During the pilot study phase, we will recruit 50 patients. The primary endpoint is hospitalization for heart failure or heart failure relapse within 12 months. Secondary endpoint is major adverse cardiovascular events, including cardiovascular mortality, myocardial infarction, stroke, sustained atrial tachycardia, or ventricular tachycardia. The results will be analyzed using intention-to-treatment analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The study will provide important evidence of whether it is safe and effective to halve the dosage of neurohumoral blockades in recDCM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>ChiCTR2100054051 (<jats:ext-link>www.chictr.org.cn<\/jats:ext-link>)<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.966537","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T06:24:16Z","timestamp":1660285456000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Maintenance of recovered dilated cardiomyopathy patients with half-dose neurohumoral blockades (MED-CHARM): A protocol for an open-label, pilot, randomized trial"],"prefix":"10.3389","volume":"9","author":[{"given":"Pengda","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhexue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","article-title":"Report of the 1995 world health organization\/international society and federation of cardiology task force on the definition and classification of cardiomyopathies","volume":"93","author":"Richardson","year":"1996","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the global burden of disease study 2015","volume":"388","author":"Disease","year":"2016","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.hlc.2014.02.022","article-title":"Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China","volume":"23","author":"Liu","year":"2014","journal-title":"Heart Lung Circ."},{"key":"B4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ejhf.16","article-title":"Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years","volume":"16","author":"Merlo","year":"2014","journal-title":"Eur J Heart Fail."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jacc.2020.05.075","article-title":"Heart failure with recovered left ventricular ejection fraction: JACC scientific expert panel","volume":"76","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet."},{"key":"B8","first-page":"ii5","article-title":"Contemporary management of heart failure in clinical practice","volume":"88","author":"Cleland","year":"2002","journal-title":"Heart."},{"key":"B9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","article-title":"The EuroHeart Failure Survey programme\u2014a survey on the quality of care among patients with heart failure in Europe Part 2: treatment","volume":"24","author":"Komajda","year":"2003","journal-title":"Eur Heart J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.ijcard.2012.06.116","article-title":"Discontinuation of beta-blockers in cardiovascular disease: UK primary care cohort study","volume":"167","author":"Kalra","year":"2013","journal-title":"Int J Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1008","DOI":"10.1016\/S2214-109X(18)30306-1","article-title":"Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study","volume":"6","author":"Teng","year":"2018","journal-title":"The Lancet Global Health."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/eurheartj\/ehx026","article-title":"Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study","volume":"38","author":"Ouwerkerk","year":"2017","journal-title":"Eur Heart J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ahj.2017.04.010","article-title":"Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry","volume":"189","author":"DeVore","year":"2017","journal-title":"Am Heart J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/ejhf.1869","article-title":"Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT-CHF and ASIAN-HF registries","volume":"22","author":"Ouwerkerk","year":"2020","journal-title":"Eur J Heart Fail."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1093\/eurheartj\/ehaa731","article-title":"Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice","volume":"41","author":"Butler","year":"2020","journal-title":"Eur Heart J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.966537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T06:24:18Z","timestamp":1660285458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.966537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":15,"alternative-id":["10.3389\/fcvm.2022.966537"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.966537","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"article-number":"966537"}}